The combination of polyphyllin VII and gefitinib can enhance the accumulation of p21 by mediating its binding to CDK/Cyclin complexes, inhibiting the activity of CDK2/4 and Cyclin D1/E in resistant cells, and preventing the degradation of p21 [57]
Current trials also exclude people with diabetes, recent heart problems, and eating disorders, which may indicate future contraindications once approved
2022;387(3):205-216 (SURMOUNT-1, tirzepatide)
HD is caused by an expanded CAG repeat in the huntingtin (HTT) gene, leading to the production of a mutant huntingtin protein with toxic gain-of-function properties
6 Since then, states have altered their positions on covering anti-obesity GLP-1 therapies: Four have withdrawn coverage entirely (California, New Hampshire, Pennsylvania, and South Carolina), three have added coverage (Missouri, Tennessee, and Utah), and at least two states (Michigan and Virginia) have enacted more narrow utilization criteria, limiting future use to those with morbid obesity
